{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:00:20Z","timestamp":1761894020195},"reference-count":62,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2004,10,19]],"date-time":"2004-10-19T00:00:00Z","timestamp":1098144000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2004,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The authors describe a 21\u2010year\u2010old man with long\u2010lasting Evans syndrome refractory to corticosteroids and immunosuppressive agents; the patient responded to four weekly infusions of rituximab. The patient relapsed with thrombocytopenia 7 months post\u2010therapy and was successfully re\u2010treated with two weekly doses of the same monoclonal antibody. He remains in remission for 7\u2010plus months after the second treatment. Therapy was well tolerated, and no infectious complications occurred, despite avoiding administration of prophylactic gammaglobulin. Rituximab appears safe and modestly effective in a variety of immune\u2010mediated hematologic diseases, including autoimmune hemolytic anemia, chronic immune thrombocytopenia, Evans syndrome, pure red cell aplasia, mixed type II cryoglobulinemia, cold agglutinin disease, and Waldenstr\u00f6m's macroglobulinemia. However, as most of the published literature consists of case reports and small case series, international collaboration is essential in order to better define the efficacy and safety of this agent in children and adults with hematologic diseases. Am. J. Hematol. 77:303\u2013310, 2004. \u00a9 2004 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ajh.20180","type":"journal-article","created":{"date-parts":[[2004,10,19]],"date-time":"2004-10-19T16:17:48Z","timestamp":1098202668000},"page":"303-310","source":"Crossref","is-referenced-by-count":32,"title":["Rituximab for refractory Evans syndrome and other immune\u2010mediated hematologic diseases"],"prefix":"10.1002","volume":"77","author":[{"given":"Elpis","family":"Mantadakis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vassiliki","family":"Danilatou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eftichia","family":"Stiakaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Kalmanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,10,19]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDECC2B8 (Rituximab) anti\u2010CD20 monoclonal antibody therapy in patients with relapsed low\u2010grade non\u2010Hodgkin's lymphoma","volume":"6","author":"Maloney DG","year":"1997","journal-title":"Blood"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703237"},{"issue":"5","key":"e_1_2_1_5_2","first-page":"66","article-title":"Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma","author":"Grillo\u2010Lopez AJ","year":"1999","journal-title":"Semin Oncol"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.268"},{"key":"e_1_2_1_7_2","first-page":"189","article-title":"B\u2010cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia","volume":"87","author":"Zaja F","year":"2002","journal-title":"Haematologica"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06573-4"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3547"},{"key":"e_1_2_1_10_2","first-page":"223","article-title":"Rituximab chimeric anti\u2010CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders","author":"Trape G","year":"2003","journal-title":"Hematologica"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402676"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02873-4.x"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0007-1048.2002.03436.x"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.1096a"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703371"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03278.x"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002770000251"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002770100340"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.4065\/78.11.1340"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.4.952"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2001.066006408.x"},{"key":"e_1_2_1_22_2","first-page":"215","article-title":"Anti\u2010CD20 monoclonal antibody therapy in refractory immune thrombocytopenic purpura","volume":"87","author":"Delgado J","year":"2002","journal-title":"Haematologica"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-133-4-200008150-00011"},{"key":"e_1_2_1_24_2","first-page":"ELT02","article-title":"Immune thrombocytopenia induced by fludarabine successfully treated with rituximab","volume":"88","author":"Fernandez MJ","year":"2003","journal-title":"Haematologica"},{"key":"e_1_2_1_25_2","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1182\/blood.V100.6.2260","article-title":"Rituximab treatment of refractory fludarabine\u2010associated immune thrombocytopenia in chronic lymphocytic leukemia","volume":"100","author":"Hegde UP","year":"2002","journal-title":"Blood"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.1092"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.36892.x"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.12.3995"},{"key":"e_1_2_1_29_2","first-page":"1157","article-title":"Rituximab for the treatment of type II mixed cryoglobulinemia","volume":"84","author":"Zaja F","year":"1999","journal-title":"Haematologica"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2856"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03078.x"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2002.01667.x"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401976"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.3406_2.x"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1213"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109097770"},{"key":"e_1_2_1_37_2","first-page":"1405","article-title":"Remission of cold hemagglutinin disease induced by rituximab therapy","volume":"164","author":"Sparling TG","year":"2001","journal-title":"Can Med Assoc J (CMAJ\/JAMC)"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2001.2622-3.x"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0018"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03537_6.x"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008350208019"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.09.039"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2002.n.022"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2003.50070"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02086.x"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1023912425610"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10947"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200101043440120"},{"key":"e_1_2_1_49_2","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1182\/blood.V96.3.1184.015k54_1184_1186","article-title":"Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab","author":"Sharma VR","year":"2000","journal-title":"Blood"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03778.x"},{"key":"e_1_2_1_51_2","first-page":"894","article-title":"Fatal visceral varicella\u2010zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma","volume":"85","author":"Bermudez A","year":"2000","journal-title":"Haematologica"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2257.2001.00397.x"},{"key":"e_1_2_1_53_2","first-page":"1006","article-title":"Rituximab for refractory childhood autoimmune hemolytic anemia","author":"Motto DG","year":"2002","journal-title":"Isr Med Assoc J"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1086\/345746"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200109273451315"},{"key":"e_1_2_1_56_2","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood.V100.6.2257","article-title":"Rituximab treatment results in impaired secondary humoral immune responsiveness","volume":"100","author":"Van der Kolk LE","year":"2002","journal-title":"Blood"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1532"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200004)43:4<834::AID-ANR14>3.0.CO;2-H"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0450"},{"key":"e_1_2_1_60_2","first-page":"4668a (abstract","article-title":"Acute agranulocytosis (AA) in three patients treated with rituximab for non\u2010Hodgkin lymphoma","author":"Voog E","year":"2001","journal-title":"Blood"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199709000-00005"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1097\/00129689-200302000-00011"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb07880.x"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.20180","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.20180","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T23:25:19Z","timestamp":1700263519000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.20180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10,19]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,11]]}},"alternative-id":["10.1002\/ajh.20180"],"URL":"https:\/\/doi.org\/10.1002\/ajh.20180","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10,19]]}}}